As of Thursday close, Inovio Pharmaceuticals Inc.’s (NASDAQ:INO) stock was down -$0.01, moving down -0.82 percent to $0.47. The average number of shares traded per day over the past five days has been 2,925,680 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.0299 fall in that time frame. In the last twenty days, the average volume was 3,417,605, while in the previous 50 days, it was 9,573,340.
Since last month, INO stock retreated -11.00%. Shares of the company fell to $0.4400 on 07/05/23, the lowest level in the past month. A 52-week high of $2.82 was reached on 01/13/23 after having rallying from a 52-week low of $0.38. Since the beginning of this year, INO’s stock price has dropped by -69.76% or -$1.0883, and marked a new high 7 times. However, the stock has declined by -83.27% since its 52-week high.
INO stock investors should be aware that Inovio Pharmaceuticals Inc. (INO) stock had its last reported insider trading activity 60 days ago on Jun 05. Zoth Lota S., the Director of the company, disposed of 5,700 shares for $0.56 on Jun 05. It resulted in a $3,192 divestment by the insider. Weiner David B. sold 5,833 shares at an average price of $1.15 on Mar 13. The insider now owns 910,124 shares following the transaction. On Feb 27, Director Weiner David B. sold 11,668 shares at $1.28 apiece. The transaction was valued at $14,935.
Valuation Metrics
The stock’s beta is 0.96. Besides these, the trailing price-to-sales (P/S) ratio of 11.63, the price-to-book (PB) ratio of 0.61.
The latest dividend of $0.0690 per share was paid out, remained unchanged from last year’s $0.0690.
Financial Health
In the three months ended March 30, Inovio Pharmaceuticals Inc.’s quick ratio stood at 4.20, while its current ratio was 4.20, showing that the company is able to pay off its debt. Based on annual data, INO earned $277.84 million in gross profit and brought in $10.26 million in revenue.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. INO’s revenue rose 25.0% to $11.48 million during the quarter, while net income inched up to $2.32 million. While analysts expected Inovio Pharmaceuticals Inc. to report -$0.14 quarterly earnings, the actual figure was -$0.16 per share, beating the consensus estimate by -14.30%. During the quarter, the company generated -$43.96 million in EBITDA. The liabilities of Inovio Pharmaceuticals Inc. were 67.37 million at the end of its most recent quarter ended March 30, and its total debt was $31.16 million. The value of shareholders’ equity is $262.74 million.
Technical Picture
This quick technical analysis looks at Inovio Pharmaceuticals Inc.’s (INO) price momentum. With a historical volatility rate of 56.73%, the RSI 9-day stood at 38.45% on 03 August.
With respect to its five-day moving average, the current Inovio Pharmaceuticals Inc. price is down by -5.96% percent or -$0.0299. At present, INO shares trade -5.38% below its 20-day simple moving average and -58.26% percent below its 100-day simple moving average. However, the stock is currently trading approximately -29.86% below its SMA50 and -69.76% below its SMA200.
Stochastic coefficient K was 13.61% and Stochastic coefficient D was 25.60%, while ATR was 0.0431. Given the Stochastic reading of 7.85% for the 14-day period, the RSI (14) reading has been calculated as 41.95%. As of today, the MACD Oscillator reading stands at -0.0198, while the 14-day reading stands at -0.0360.
Analyst Ratings
Inovio Pharmaceuticals Inc. downgraded its rating on Inovio Pharmaceuticals Inc. (NASDAQ: INO) to a Hold in a note to investors on November 09, 2022. The analysts firm previously had a Buy rating on the stock.Inovio Pharmaceuticals Inc. (INO) has been rated Hold by analysts. According to 0 brokerage firms, INO is a sell, and 4 firms recommend it is a Hold. There are 1 analyst who say the stock is underweight. A total of 0 analysts rate Inovio Pharmaceuticals Inc. stock as buy, with 0 recommending it as overweight.
With a median target price of $1.00, the current consensus forecast for the stock is $1.00 – $2.00. Based on these forecasts, analysts predict Inovio Pharmaceuticals Inc. (INO) will achieve an average price target of $1.33.
